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Cells synthesize large amounts of protein in a very short time, in a
cytosol where protein concentration at steady state approaches 300 g/l
[1]. Under these conditions,manyhydrophobic surfaces on proteinsmay
be transiently exposed and the likelihood of deleterious interactions is
quite high [2]. To counter this threat to cell viability, molecular
chaperones have evolved to help nascent polypeptides fold correctly
and multimeric protein complexes assemble productively, while
minimizing the danger of protein aggregation. Heat shock protein 90
(Hsp90) is an evolutionarily conserved molecular chaperone that is
involved in stabilizing and activating at least two hundred signaling
proteins (clients) under normal cellular conditions [3–5]. An updated list
of Hsp90 clients can be found at http://www.picard.ch/downloads/
downloads.html. Cancer cells have co-optedHsp90 to serve a crucial role
in protecting an array ofmutated and over-expressed oncoproteins from
misfolding and degradation [6,7]. Thus, Hsp90 inhibitors are being
actively evaluated as novel cancer therapeutics [8,9]. This review
describes advances in our understanding of how cytosolic and nuclear
Hsp90 is regulated by post-translational modiﬁcation in lower and
higher eukaryotes.2. Hsp90 structure and the chaperone cycle
Hsp90 is found in all kingdoms except Archaea [10]. In humans, as in
other eukaryotes, there are two cytosolic Hsp90 isoforms: stress-
induced Hsp90α and constitutively expressed Hsp90β [11]. Hsp90 is a
member of the ATPase/kinase GHKL (Gyrase, Hsp90, Histidine Kinase,
MutL) superfamily — a group of proteins that are characterized by a
unique ATP binding cleft [4,12]. Hsp90 is comprised of three domains: i)
an N-terminal domain, containing nucleotide, co-chaperone (proteins
that assist Hsp90 in modulating client activity), and drug binding sites;
ii) amiddle (M) domain,whichprovides binding sites for client proteins
and other co-chaperones; iii) a C-terminal domain containing a
dimerization motif and binding sites for yet other co-chaperones
(Fig. 1) [13–15]. Hsp90 proteins also have an unstructured charged-
linker region of signiﬁcant but variable length that connects N and M
domains and provides conformational freedom to the protein [16,17].
Various biophysical techniques, such as X-ray crystallography,
small angle X-ray scattering (SAXS) analysis, and electron microscopy
have provided valuable snap shots of different Hsp90 conformations
in the presence or absence of nucleotides and different co-chaperones
[13,18–22]. From these data, investigators have proposed that Hsp90
cycles through several conformations that ultimately result in
correctly orienting N and M domains to form a split ATPase. Indeed,
much accumulated data support the hypothesis that Hsp90 chaperone
function relies on ATP binding and hydrolysis (Fig. 1) [12]. However,
although all Hsp90 proteins can hydrolyze ATP, the rates of hydrolysis
are low and variable from one species to another (0.0015 s−1 for
human Hsp90α and 0.013 s−1 for yeast Hsp90) [19,23]. Recent
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Fig. 1. Post-translational modiﬁcation of Hsp90 ﬁne-tunes its chaperone function. ATP
binding to the N-terminal domain of Hsp90 (gray) promotes transient dimerization of
the N-domains (closed conformation). Subsequent structural rearrangements establish
the ‘closed and twisted’ conformation capable of ATP hydrolysis. The co-chaperone
Aha1 enhances Hsp90 ATPase activity by facilitating the conformational changes
necessary to achieve ATPase competence, while Sti1 and Hsp90 inhibitors such as
geldanamycin (GA) or radicicol (RD) exert the opposite effect by inhibiting the initial
structural changes necessary for N-domain dimerization. p23 slows ATP hydrolysis at a
late stage of the chaperone cycle. Domain labeling is as follows: N, N-domain (gray); CL,
charged linker (yellow); M, M-domain (amber); C, C-domain (green).
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comprising the chaperone cycle in the absence of nucleotides [24].
Current data suggest that ATP binding and hydrolysis subtly shift the
conformational equilibrium, presumably by lowering the energy
barrier between certain conformations, thus providing directionality
to the Hsp90 cycle [24,25]. Hsp90 inhibitors such as radicicol (RD) or
geldanamycin (GA) disrupt the chaperone cycle by replacing ATP in
Hsp90's nucleotide binding pocket [26,27].
Studies using ﬂuorescence resonance energy transfer (FRET) have
revealed that nucleotides and co-chaperones (Aha1, p23 and Sti1)
modulate Hsp90 conformational dynamics in real time [24,25]. Further,
although the essential aspects of the Hsp90 conformational cycle are
conserved from bacteria to humans, the population dynamics (which
conformational states aremost occupied at steady state) differ between
bacteria, yeast, and human Hsp90 [19]. These data suggest that the
Hsp90 cycle may be tunable and tailored to the unique intracellular
environment of different organisms, or to discrete physiological states
within different tissues of metazoans (such as the distinct intracellular
environment that is characteristic of cancer). This ﬁne-tuning is likely
provided by complex post-translational modiﬁcations to Hsp90 itself
and to other components of the chaperone machinery.3. Post-translational modiﬁcation of Hsp90 co-chaperones
3.1. Co-chaperones modulate Hsp90 activity
Co-chaperones can be generally deﬁned as proteins that modulate
the function of other chaperones [28]. Depending on its conforma-
tional state, Hsp90 normally interacts with distinct co-chaperones
with diverse activities. In total, these conformation-speciﬁc multi-
protein complexes comprise the functional chaperone unit, frequently
referred to as the ‘Hsp90 chaperone machine’. Co-chaperones contain-
ing tetratricopeptide repeat (TPR) domains use this motif to interact
with Hsp90 (e.g., p60Hop/Sti1, Chip, FKBP51 and 52, PP5/Ppt1), andthey have additional domains that catalyze reactions as diverse as
ubiquitin ligation, dephosphorylation, andpeptidylprolyl isomerization.
Non-TPR-co-chaperones include Aha1/Hch1, p23 (prostaglandin E
synthase 3, PGES3)/Sba1, Sgt1, and p50/Cdc37 [29–45]. A number of
co-chaperones modulate Hsp90 ATPase activity, thereby altering the
cycling rate of the chaperone machine (e.g., p50/Cdc37, p60Hop/Sti1,
p23, Aha1).ManyHsp90 co-chaperones are conserved in all eukaryotes.
For this reason, the single cell eukaryote baker's yeast, Saccharomyces
cerevisiae, has proven to be an excellent model organism to study the
function of both Hsp90 and its co-chaperones in maintaining cellular
homeostasis [46–51].
3.2. Impact of co-chaperone phosphorylation on Hsp90 function
One of the challenging tasks in understanding the role of co-
chaperones in controlling Hsp90 activity in normal and cancer cells is
to understand the functional consequences of co-chaperone post-
translational modiﬁcations. While this has only recently been
appreciated, recent work by Vaughan and colleagues [36] emphasizes
its importance. These investigators showed that co-chaperones Cdc37
and PP5/Ppt1 form complexes with Hsp90 in yeast and in human
tumor cells. The protein phosphatase PP5/Ppt1 dephosphorylates the
Ser-13 residue on Cdc37 in vivo, directly affecting its interaction with
Hsp90 and negatively impacting the chaperoning of numerous kinase
clients by the Hsp90–Cdc37 complex. Serine phosphorylation of
Cdc37, mediated by casein kinase 2 (CK2), is necessary for it to
chaperone numerous kinase clients including CK2 itself, Cdc28Cdc2,
Ste11RAF, Kin28 andMps1, and also for binding toHsp90 [52–54]. Thus,
Cdc37 phosphorylation status is likely to affect cellular sensitivity to
Hsp90 inhibition. Indeed, the cellular toxicity of GA is markedly
enhanced in cells expressingCdc37–S13A [36]. Further, over-expression
of PP5/Ppt1 is synthetically lethal with GA in yeast. In cancer cells, PP5
over-expression correlated with reduced Cdc37 phosphorylation,
reduced Raf-1 protein (an Hsp90 client) expression, and reduced
activity of the MAP kinase pathway [36].
Another example of co-chaperone post-translational modiﬁcation
impacting Hsp90 function is supplied by an elegant study recently
published byBansal and colleagues [55]. They showed that dimerization
of Sgt1 is negatively regulated by CK2-mediated phosphorylation at
Ser-361. This in turn affects kinetochore assembly, which requires a
functional Sgt1/Hsp90 complex and which is essential for proper
chromosome segregation during cell division in eukaryotes [55].
CK2 also phosphorylates p23, on Ser-113 and Ser-118 in vivo [56].
This is important for its prostaglandin synthase activity and is required
for the formation, in this context, of a tertiary complex between p23, CK2
and Hsp90 [56]. Finally CK2 and pp90rsk can also phosphorylate murine
Sti1 (mSti1) in vitro (on Ser-189), affectingmSti1 binding to Hsp90 [57].
Cdc2 is also able to phosphorylate mSti1 at Thr-198 in vitro, suggesting
that mSti1 phosphorylation may play a role in cell cycle regulation [58].
The immunophilin FK506 binding protein 52 (FKBP52) binds to
Hsp90 via its TPR domain and is important for chaperoning of steroid
hormone receptors. CK2 phosphorylates FKBP52 on Thr-143 both in
vitro and in vivo. Phosphorylation of this residue does not affect FK506
binding to FKBP52, but phosphorylated FKBP52 does not interact with
Hsp90. These ﬁndings suggest that phosphorylation of FKBP52 plays a
role in modulating steroid hormone receptor-mediated signal trans-
duction [52,59].
FKBP52 phosphorylation (residues not speciﬁed) also plays a
role in the transduction efﬁciency of adeno-associated virus type 2
(AAV) [60–62]. AAV is considered to be a potential tool for gene
therapy, since it is a non-pathogenic single-stranded DNA virus that
can integrate into the human genome in a site-speciﬁc manner. Its
transduction efﬁciency is cell typedependent and relies on the synthesis
of a second strand of viral DNA. Phosphorylated FKBP52 regulates this
process by binding the D-sequence in the inverted terminal repeat of
AAV and inhibiting synthesis of the second DNA-strand, negatively
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post-translational modiﬁcations is likely to uncover additional impor-
tant regulatory mechanisms affecting Hsp90.
4. Post-translational modiﬁcation of Hsp90
4.1. Phosphorylation
Hsp90 is subject to variouspost-translationalmodiﬁcations including
phosphorylation, acetylation, S-nitrosylation, oxidation, and ubiquitina-
tion that impact chaperone function in numerous ways (Fig. 2) [63].
Hsp90 is a phosphoprotein and its steady-state phosphorylation level is
inﬂuenced by different cellular environments in a species-speciﬁc
manner. For example, heat shock decreases the turnover of Hsp90
phosphate groups in yeast cells,while this processhas theopposite effect
on HeLa cell Hsp90 phosphorylation [64,65]. A number of serine,
threonine, and tyrosine phosphorylation sites have been identiﬁed in
Hsp90 [64,66–77]. Early work showed that Hsp90 became hyper-
phosphorylated and associated less avidly with its client kinase p60v-src
in NIH 3T3 cells treatedwith the serine/threonine phosphatase inhibitor
okadaic acid, suggesting a link between Hsp90 phosphorylation and its
ability to chaperone client proteins [66,78]. Supporting these data, the
co-chaperone PP5/Ppt1 dephosphorylates Hsp90 in vitro and positively
regulates its chaperone activity in vivo [74,75,79].Hsp90α H
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Fig. 2. Post-translational modiﬁcation sites on Hsp90. Domain location of phosphorylated s
lysine (K) residues (pale blue), S-nitrosylated cysteine (C) (green) and cysteine oxidation si
sites, the reader is referred to [64,76].Tyrosine phosphorylation of Hsp90 has been shown to affect its
interaction with distinct client proteins. Thus, Hsp90 tyrosine phos-
phorylation induced by 3-hydroxy-3-methylglutaryl-coenzyme A re-
ductase inhibitors (statins)was reported to increase its associationwith
endothelial nitric oxide (eNOS) [80]. Tyrosinephosphorylation of Hsp90
was also shown to enhance its interaction with ionotropic P2X7
receptors [69]. Geldanamycin treatment decreased both Hsp90 tyrosine
phosphorylation and association with P2X7 receptors [69]. A series of
recent proteomic studies have identiﬁed a large number of phospho-
sites on Hsp90, but the protein kinases targeting many of these sites
remain unknown [81–101]. A comprehensive list of these phosphory-
lation sites can be found in a recent review [76].
As can be appreciated by referring to the speciﬁc examples provided
below, phosphorylation of speciﬁc residues in Hsp90 can affect client
protein interaction (CK2-mediated charged linker phosphorylation)and
can provide a mechanism to regulate the chaperoning of different
classes of client proteins by Hsp90 (CK2-mediated andWee1-mediated
N-domain phosphorylation). Certainly, additional functional conse-
quences of Hsp90 phosphorylation will become apparent as these
investigations continue.
4.1.1. Double-stranded DNA protein kinase
Elegant work by Lees-Miller and Anderson has shown that double-
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(Thr-5 and Thr-7) found only in the N domain of human Hsp90α.
Equivalent residues in mouse Hsp86 and rabbit Hsp90α are also
phosphorylated by DNA-PK [102]. The physiologic signiﬁcance of
Hsp90α phosphorylation by DNA-PK remains to be resolved, although
cellular DNA damage has been reported to alter Hsp90 phosphory-
lation [81,96].
4.1.2. B-Raf and Akt kinases
Functional proteomics studies have identiﬁed B-Raf and Akt, both
Hsp90 clients, as able to phosphorylate Hsp90. Old and colleagues
identiﬁed Hsp90α Ser-263 as one of the targets of B-Raf in melanoma
cells [72]. It would be valuable to know the impact of this phosphor-
ylation on Hsp90 chaperone function and drug binding. A similar study
recently reported that the serine–threonine protein kinase Akt phos-
phorylates several chaperone proteins, including Hsp90α, Hsp90β,
Glucose-regulated protein (Grp) 78, Grp94, Hsp70, and protein disulﬁde
isomerase (PDI), in rat mesangial cells [103]. Mesangial cells contribute
to glomerular injury through their ability to undergo proliferation and
hypertrophy. Akt plays a major role in these processes and it remains to
be seen whether Akt-mediated chaperone phosphorylation contributes
to glomerular injury [103].
4.1.3. c-Src kinase
While somestudies suggest a negative impact of de-regulatedHsp90
phosphorylation on chaperone function, recent work has shown that
phosphorylation of discrete residues on Hsp90 may stimulate chaper-
one activity. Duval and co-workers have shown that c-Src kinase,
another Hsp90 client, phosphorylates Hsp90β Tyr-301 in response to
vascular endothelial growth factor receptor-2 (VEGFR-2) activation
[70]. This leads to increased association betweenHsp90β and eNOS, and
results in increased eNOS activity, and nitric oxide (a vasodilator)
production and release from endothelial cells. Hsp90β Tyr-301 is con-
served in otherHsp90proteins (it corresponds to Tyr-309 inHsp90α). It
will be interesting to determinewhether this residue inHsp90α is also a
target for c-Src, and if so what are the functional consequences of its
phosphorylation.
4.1.4. Protein kinase A (PKA)
A systematic phospho-proteomics approach has identiﬁed Hsp90β
Ser-452 to be phosphorylated by PKA in vitro [104]. Interestingwork by
Lei and colleagues has shown that diabetes mellitus or hyperglycemia
can activate PKA phosphorylation of Hsp90α at Thr-90 in rat aortic
endothelial cells [105]. This was associated with Hsp90α translocation
to the cell surface [105]. Diabetes mellitus and hyperglycemia both
reduce the bioavailability of nitric oxide by inhibiting eNOS activity.
These investigators have proposed that PKA-mediated phosphorylation
of Hsp90α reduces the amount of the chaperone that is available to
associate with and activate eNOS, thus contributing to reduced eNOS
activity and a decline in nitric oxide production in the aortic
endothelium of diabetic rats [105]. The role of PKA in Hsp90α secretion
was further explored byWangand colleagues. Theyhave conﬁrmed that
cellular secretion of Hsp90α is stimulated by PKA-mediated phosphor-
ylation of Thr-90 [74]. Phosphorylation-dependent regulation of Hsp90
secretion in keratinocytes and cancer cells may also play an important
role in wound healing and tumor metastasis, respectively [82,106,107].
4.1.5. CK2 protein kinase
CK2 is a ubiquitous serine–threonine, acidophilic kinase whose
activity depends on Hsp90 chaperone function [52,108,109]. Lees-Miller
and Anderson have shown that CK2 phosphorylates two serine residues,
Ser-231 and Ser-263, in the charged-linker of Hsp90α [110]. Equivalent
residues in Hsp90β (Ser-226 and Ser-255) are also phosphorylated in
untransformed cells but not in leukemic cells [111]. The leukemogenic
kinases, Bcr-Abl, FLT3/D835Y, and Tel-PDGFRβ, all suppress constitutive
phosphorylation of Hsp90β at these sites, and this leads to inhibition ofapoptosome function. This is achieved by stabilization of a strong
interaction between Hsp90β and apoptotic peptidase activating factor 1
(Apaf-1), which prevents cytochrome c-induced Apaf-1 oligomerization
and caspase-9 recruitment. Stabilization of the Hsp90β-apoptosome
interaction by suppression of Ser-226 and Ser-255 phosphorylationmay
contribute to chemoresistance in leukemias [111].
It would be of interest to know the impact of these serine phos-
phorylations on Hsp90 secretion, since these serine residues are
contained within the charged-linker region, a motif that has been
previously implicated in modulating Hsp90 secretion [16]. Ck2 phos-
phorylationof the charged linker is also important for functionof the aryl
hydrocarbon receptor (AhR) [78]. This is a ligand-activated transcription
factor that regulates genes involved in xenobiotic metabolism. The
cytosolic AhR exist as a complex with Hsp90 and hepatitis B virus
X-associated protein 2 (XAP2) [78]. Phosphorylation of Hsp90α Ser-231
andHsp90β Ser-226 and Ser-255 caused dissociation of the AhR–Hsp90
complex and destabilization of AhR protein. Mutation of these residues
to non-phosphorylatable alanine increased the transcriptional activity of
AhR and stabilized its interaction with Hsp90 [78].
We have recently shown that CK2 also phosphorylates a conserved
threonine residue (Thr-22) in the N-domain of yeast Hsp90 both in vitro
and in vivo. Thr-22 is the only threonine residue in the N-domain
targeted by CK2. This residue, together with adjacent amino acids,
participates in an important hydrophobic interaction with the catalytic
loop in the middle domain of Hsp90. We recently showed that ATP
binding and not N-domain dimerization of Hsp90 is a prerequisite for
CK2-mediated phosphorylation of Thr-22 [75,76]. Mutation of this
residue to a non-phosphorylatable alanine (T22A) did not affect Hsp90
ATPase activity,while thephospho-mimeticmutant (T22E)hadonly 40%
of wild type ATPase activity. These mutants in yeast, and the equivalent
mutations in human Hsp90α (T36A and T36E), affected Hsp90-
dependent chaperoning of kinase (v-Src, Mpk1/Slt2, Raf-1, ErbB2 and
CDK4) and non-kinase (heat shock factor 1, cystic ﬁbrosis transmem-
brane conductance regulator protein, glucocorticoid receptor) clients
[75,76]. In addition, Thr-22 phosphorylation status also contributes to
Hsp90 inhibitor sensitivity [76]. Finally, we observed that mutation of
this residue in both yeast and human Hsp90 signiﬁcantly reduced
interaction with the co-chaperone Aha1, and the chaperoning defects of
Thr-22 Hsp90 mutants were corrected by over-expressing Aha1 [75].
Clearly, CK2 phosphorylation of serine and threonine residues in Hsp90
represents an important but complex regulatory component of chaper-
one function in eukaryotic cells.
4.1.6. Swe1Wee1 kinase
Swe1 (Saccharomyces Wee1)/Wee1 tyrosine kinase is an Hsp90
client that regulates the G2/M cell cycle transition by phosphorylating
Cdc28Cdc2 [112–114]. Swe1 also directly phosphorylates a conserved
tyrosine residue (Tyr-24 in Hsp82 and Tyr-38 in Hsp90α) in the
N-domain of yeast and human Hsp90 both in vitro and in vivo [77]. In
yeast cells, Swe1-mediated phosphorylation of Hsp90 occurs in S
phase of the cell cycle and causes Hsp90 to translocate from nucleus to
cytoplasm, where it is polyubiquitinated and degraded by protea-
somes. This is the “switching off” mechanism for this population of
Hsp90, since no tyrosine phosphatase capable of dephosphorylating
Tyr-24/Tyr-38 could be identiﬁed. Tyrosine 24 is among a group of
residues that have been shown to form an interacting cluster in ATP-
bound Hsp90 [115]. The hydrophobic interactions established by this
cluster are essential for N-domain dimerization and are necessary for
active site formation and forATPase activity [115,116]. Swe1Wee1 targets
Tyr-24/Tyr-38 when Hsp90 is in an “open” (N-domain undimerized)
conformation, since Tyr-24/Tyr-38 is not accessible when Hsp90
assumes the “closed” (N-domain dimerized) conformation [77].
Mutation of this residue to a non-phosphorylatable amino acid reduces
Hsp90 binding to Aha1 and Sba1/p23 co-chaperones. Phospho-mimetic
mutation positively affects the ability of Hsp90 to chaperone a selected
group of client proteins, including the kinases ErbB2, Raf-1, and Cdk4,
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andWee1 silencing or pharmacologic inhibition in prostate and cervical
carcinomacells, sensitizes these cells toHsp90 inhibitors. This suggests a
novel therapeutic strategy to increase the cellular potency of Hsp90
inhibitors [77].
4.2. Acetylation
Acetylation is a post-translational modiﬁcation that adds acetyl
groups to proteins, usually on lysine residues. Histones are a major
acetylation target and, historically, acetylating enzymes were termed
histone acetylases (HAT) and deacetylating enzymes were termed
histone deacetylases (HDAC). However, these enzymes are now
known to be capable of modifying numerous non-histone proteins
including Hsp90. Yu and colleagues were ﬁrst to report Hsp90
acetylation in response to HDAC inhibitors (HDACi). These investiga-
tors showed that the HDACi depsipeptide (Romidepsin) increased
steady state acetylation of Hsp90 while simultaneously destabilizing
Hsp90 interaction with several client proteins, including ErbB2, Raf-1,
and mutant p53 [117]. Hsp90 acetylation was also correlated with
decreased binding to ATP. Others have shown that additional HDACi
also cause Hsp90 hyper-acetylation [118,119].
4.2.1. Acetylases and deacetylases targeting Hsp90
p300 and HDAC6 promote acetylation and deacetylation of Hsp90,
respectively [120–123]. Acetylated Hsp90 levels are increased in
HDAC6-deﬁcient mouse embryonic ﬁbroblasts and glucocorticoid
receptor function in these cells is compromised [124]. Androgen
receptor, an Hsp90 client, is also down-regulated upon HDAC6
inhibition [125]. Reduction in HDAC6 expression also promotes
destabilization of another Hsp90 client protein, the hypoxia-inducible
transcription factor HIF-1α [126]. HDAC6 and HDAC10 have been
shown to regulate Hsp90 mediated VEGF receptor regulation [127].
Finally, recent work by de Zoeten et al. has shown that pharmacologic
inhibition or genetic deletion of HDAC6 increased acetylation of Foxp3
and Hsp90 both in vitro and in vivo. This in turn increased the immune
suppressive activity of Foxp3+ T-regulatory (Treg) cells [128]. Foxp3+-
Tregs are essential to immunehomeostasis, and if diminished innumber
or function can cause autoimmunity and allograft rejection. Therefore,
speciﬁc targeting of HDAC6, or its downstream target, HSP90, can
promote Treg-dependent suppression of autoimmunity and transplant
rejection [128].
Although the impact of HDAC6 on Hsp90 acetylation has been
extensively studied, other HDACs also are able to deacetylate the
chaperone. HDAC1 has been reported to deacetylate Hsp90 in the
nucleus of human breast cancer cells [129], and both HDAC1 and
HDAC10 inhibit the productive Hsp90 chaperoning of VEGF receptor
proteins [127]. Thus, different HDACs may alter Hsp90 acetylation
status in distinct cellular locations and thus likely for distinct
purposes. It is not yet clear which HDACs affect the acetylation status
of individual lysine residues discussed below, nor is it knownwhether
any redundancy exists for deacetylation of particular sites.
4.2.2. Acetylation of speciﬁc lysine residues on Hsp90
Treating SkBr3 breast cancer cells with the pan HDACi trichostatin A
(TSA) caused hyperacetylation of Hsp90α at lysine 294 [130].
Interestingly, K294 acetylation can be detected even in the absence of
HDACi, suggesting that a pool of Hsp90may be constitutively acetylated
on this lysine residue [130]. K294Q or K294A Hsp90α mutants
(acetylated lysine mimics) displayed reduced interaction with numer-
ous client proteins (ErbB2, p60v-Src,mutantp53, androgen receptor, Raf-
1, HIF1α) and failed to associatewith the co-chaperones Aha1, CHIP and
FKBP52. The non-acetylated mimic mutant K294R showed an equiva-
lent or stronger interactionwith these co-chaperone and client proteins
compared to wild type Hsp90 [130].Treating human embryonic kidney 293 cells (HEK293) with the
pan-HDACi Panobinostat (LBH589) led to identiﬁcation of 7 additional
acetylated lysine residues in Hsp90 [131]. Mutation of these lysine
residues to glutamine affected the binding of Hsp90α to several co-
chaperones, including CHIP, Hsp70 and p23, inhibited ATP binding,
and inhibited Hsp90 chaperoning of Raf-1 [131]. Taken together, these
data suggest that acetylation of Hsp90 is a dynamic, tightly regulated
process that impacts multiple aspects of Hsp90 function. In general,
acetylation of Hsp90 results in a lost or weakened interaction with its
client proteins, leading to their instability and degradation.
What are the functional consequences of Hsp90 acetylation in
yeast? When expressed on a single copy plasmid under a glycerol-3-
phosphate dehydrogenase (GPD1) promoter, human Hsp90α did not
optimally support yeast growth and K294R was inviable. Hsp90α-
K294Q, however, was functional in yeast [130]. Hsp90α-K294R
remained inviable when expressed on a single copy plasmid under a
HSC82 promoter, although the difference in chaperone activity of
Hsp90α wild type and K294Q mutant was less marked. In contrast,
yeast expressing R or Q mutations to the equivalent residue of yeast
Hsp90 (K274) are both viable (manuscript in preparation). These
results suggest that acetylation of this conserved lysine residue likely
arose in metazoans as a unique post-translational modiﬁcation not
utilized by yeast Hsp90.
4.3. S-nitrosylation
S-nitrosylation, the covalent attachment of a nitrogen monoxide
group to the thiol side chain of cysteine, is a reversible post-translational
modiﬁcation of Hsp90, mediated by nitric oxide (NO). Martinez-Ruiz
and colleagues ﬁrst reported that NO causes S-nitrosylation of human
HSP90α in endothelial cells, and they showed that this modiﬁcation,
which inhibited chaperone activity, occurred in the C-domain of
Hsp90α at Cys-597 [132]. Because endothelial nitric oxide synthase
(eNOS) requires association with Hsp90 for its activity, these authors
proposed that NO-dependent inactivation of Hsp90 in endothelial cells
functions as a regulatory feedback mechanism to control production of
NO. Cys-597 and surrounding amino acids have been suggested by
Colombo and colleagues to represent a conformational switch region in
the Hsp90 C-domain that propagates long-range communication of
structural information to Hsp90's N-domain [116]. Recently, Retzlaff
and colleagues reported that S-nitrosylation of Cys-597 inhibits Hsp90
ATPase activity [133], conﬁrming that environmentally induced
structural cues can be propagated between spatially distant domains
of Hsp90. It is intriguing to speculate that some of the antitumor activity
of NO may reﬂect NO-mediated Hsp90 inhibition in cancer cells.
4.4. Oxidation and ubiquitination
Oxidative stress has been shown to post-translationally modify
Hsp90. For example, treating human breast cancer MDA-MB-231 cells
with tubocapsenolide A (TA), a novel withanolide, leads to a transient
increase in reactive oxygen species and a decrease in intracellular
glutathione content [134]. Consequently, this causes a direct thiol
oxidation of Hsp90. TA treatment is correlated with proteasome-
dependent degradation of the Hsp90 clients Cdk4, cyclin D1, Raf-1,
Akt, and mutant p53, suggesting that TA-induced thiol oxidation of
Hsp90 inhibits its chaperone function [134]. Oxidative stress can also
cause lipid peroxidation which leads to accumulation of thiol-reactive
α,β-unsaturated aldehydes, including 4-hydroxy-2-nonenal (4-HNE)
and 4-oxo-2-nonenal (4-ONE). 4-HNE targets Cys-572 of Hsp90 and
inhibits its ability to chaperone clients [135].
Lysines are also post-translationally modiﬁed by ubiquitination.
The photodynamic signal transduction inhibitor hypericin was shown
to increase ubiquitination of Hsp90 [136]. As a consequence, Hsp90
chaperone function was inhibited and the client proteins Raf-1,
mutant p53, Cdk4, and Plk were dissociated from Hsp90 complexes
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cancer chemotherapeutic drug Taxotere (docetaxel) inhibits VEGF-
induced human umbilical vein endothelial cell (HUVEC) migration in
vitro at concentrations substantially lower than required to cause cell
cycle arrest or apoptosis. Taxoterealsopromotes theubiquitinationand
subsequent proteasomal degradation of Hsp90 in HUVECs. Taxotere
prevents VEGF-induced phosphorylation of focal adhesion kinase, Akt,
and eNOS, all of which are Hsp90 clients [137]. This drug also blocks the
VEGF-induced increase in eNOS activity, which depends on Hsp90
interaction. Thus,Hsp90 inhibitionmay contribute to the antiangiogenic
activity of Taxotere [137]. Finally, as mentioned earlier in this review,
Swe1 phosphorylation of Hsp90 in yeast signals Hsp90 polyubiquitina-
tion and subsequent degradation by cytoplasmic proteasomes. These
data highlight the possibility of cross-talk between two distinct post-
translationalmodiﬁcations ofHsp90and their impact onHsp90 function
[77].
5. Concluding remarks
Post-translational modiﬁcations of Hsp90 make complex contri-
butions to the regulation of chaperone function since they inﬂuence
multiple regulatory factors, including ATP binding/hydrolysis and co-
chaperone binding. Nevertheless, several general conclusions can be
made. (1) The extent of Hsp90 post-translational modiﬁcations is
greater in metazoans compared to single cell eukaryotes, suggesting
that they provide an additional layer of regulation toHsp90 as its client
repertoire increased during evolution. (2) Sites that undergo post-
translational modiﬁcation are scattered throughout all domains of
Hsp90, including the charged linker. (3) Numerous Hsp90 phosphory-
lations are catalyzed by kinase clients of the chaperone, suggesting that
client-mediated phosphorylation may regulate Hsp90 chaperone activ-
ity. This hypothesis is supported by the recent observation that substrate
binding to Hsp90 can drive conformational changes in the chaperone
[138]. Current data certainly suggest that some post-translational
modiﬁcations mediated by Hsp90 clients themselves (e.g., phosphory-
lation and S-nitrosylation) may provide a feedback mechanism to
regulate client (and Hsp90) activity.
Manyquestions concerning post-translationalmodiﬁcation of Hsp90
remain unanswered. (1) The kinases, phosphatases, HATs, and HDACs
responsible for regulating post-translational modiﬁcation of many sites
on Hsp90 remain to be identiﬁed. (2) Development of phosphorylation
or acetylation site-speciﬁc antibodies to Hsp90 lags far behind the
identiﬁcation of modiﬁed sites but will be absolutely necessary to study
the impact of individual Hsp90 post-translational modiﬁcations on
subcellular localization and tissue speciﬁcity. (3) Understanding the
impact of post-translational modiﬁcation of Hsp90 (or co-chaperones)
on sensitivity to Hsp90 inhibitors is likely to provide novel strategies to
improve drug sensitivity, and also to suggest possible mechanisms of
acquired drug resistance. (4) Finally, further explication of the cross-talk
between variousHsp90 post-translationalmodiﬁcationswill greatly add
to our knowledge of the multilayered control mechanisms higher
eukaryotes have adopted to ﬁne-tune Hsp90 function in a client-, cell-,
and tissue-speciﬁc manner.
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